Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta
調査の概要
詳細な説明
Recombinant IFN alfa possesses anti-viral and immunomodulatory effects and has been shown to be effective in chronic hepatitis B [Davis et al. 1989; Bisceclie et al, 1989]. Interferon alfa is also one of the approved treatments for chronic hepatitis B. Administration of IFN alfa-2b to adults leads to disappearance of HBV DNA with or without HBeAg seroconversion in 30-50% of patients, which is two to three times above the rate of yearly spontaneous HBeAg seroconversion (10-15%). Normalization of serum ALT occurs in most cases. Loss of HBsAg is observed in 10-15% of Caucasian patients during the prolonged post-treatment follow-up period. Recently, studies suggested that a higher proportion of patients receiving pegylated IFN could achieve HBeAg seroconversion and control of HBV replication [Marcellin et al, 2004; Lau et al, 2004; Jensen et al, 2004].
RBV is another antiviral nucleotide analogue with few adverse effects [Sidwell et al, 1972; Patterson et al, 1990]. RBV alone can modestly inhibit HDV or HBV replication [Choi et al, 1989]. The beneficial effect of combined IFN plus RBV in the treatment of chronic hepatitis B has also been shown in previous studies [Cotonat et al, 2000]. Why RBV can greatly enhance the treatment efficacy is not clear. It had been shown that ribavirin could inhibit interleukin-4, an inhibitor of cytotoxic T lymphocyte activity, and preserves the interleukin-2 and gamma IFN activities. Other studies revealed that the enhanced efficacy was associated with HBV- or other virus-specific type 1 cytokine-mediated T helper cell responses [Cramp et al, 2000; Tam et al, 1999; Hultgren et al, 1998; Fang et al, 2002; Fang et al, 2000; Rico et al, 2001]. Thus, the combination therapy may augment virus-specific cytotoxic T lymphocytes and non-specific immune response, and effectively shift the immune responses to the more potent antiviral type 1 T-helper profile [Hultgren et al, 1998].
HDV, like HCV, is a RNA virus. Indeed, RBV had also been shown to be active against HDV replication in cell cultures [Choi et al, 1989]. The investigators therefore hypothesize that pegylated IFN alfa-2b in combination with RBV can yield an efficacy in chronic hepatitis D patients who are dually infected by HBV. The purpose of this protocol is to test this hypothesis. A previous study found that high-dose IFN may improve the efficacy for chronic hepatitis D patients. Another pilot study using IFN alfa plus RBV also demonstrated that the seroclearance of HCV RNA was not affected by HBV coinfection [Liu et al, 2003]. The investigators thus use pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic HDV and HBV infection.
The treatment choice for chronic hepatitis D was not clarified till now. In this proposal, the dosage and duration for the combination regimen are decided mainly by the experience from the treatment of chronic hepatitis B and chronic hepatitis C.
The investigators recent study using ribavirin and interferon (IFN) combination therapy for dual chronic hepatitis B and C suggested that combining ribavirin 1,200 mg daily for 6 months, together with 6 million units (MU) IFN-alpha 2a thrice weekly for 12 weeks and then 3 MU for another 12 weeks was effective for the clearance of HCV RNA [Liu et al, 2003]. Twenty-four patients with chronic hepatitis seropositive for both hepatitis B surface antigen and antibody to HCV received ribavirin 1,200 mg daily for 6 months, together with 6 million units (MU) IFN-alpha 2a thrice weekly for 12 weeks and then 3 MU for another 12 weeks. The serum HCV clearance rate was 43% 24 weeks posttreatment. The serum ALT normalization rate was 43% 24 weeks posttreatment. In hepatitis B and C dually infected patients, combination IFN with ribavirin can achieve a sustained HCV clearance rate comparable with hepatitis C alone. Furthermore, a previous study revealed that a 12-week RBV therapy was not effective for patients with chronic hepatitis B [Kakumu et al, 1993]. Therefore, a 24-week course of combination therapy pegylated IFN+RBV will be used.
Increased RBV dosage has been considered a contributory factor to the better efficacy in treating refractory genotype HCV. For example, recent studies suggested that using RBV 800 mg daily is adequate to treat HCV genotype non-1 while the standard dosage of RBV is required to treat HCV genotype 1 [NIH 2002]. The investigators thus propose to use RBV 1000-1200 mg daily according to the body weight of the patient.
研究の種類
入学
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Pei-Jer Chen, M.D., Ph.D.
- 電話番号:7072 886-2-23123456
- メール:peijer@ha.mc.ntu.edu.tw
研究場所
-
-
-
Taipei、台湾、100
- 募集
- National Taiwan University Hospital
-
Taipei、台湾、100
- まだ募集していません
- National Taiwan University
-
主任研究者:
- Pei-Jer Chen, M.D., Ph.D.
-
コンタクト:
- Pei-Jer Chen, M.D.; Ph.D.
- 電話番号:7072 886-2-23123456
- メール:peijer@ha.mc.ntu.edu.tw
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Be positive for both anti-HDV and HBsAg for more than 6 months
- Present with elevated serum ALT levels at least 1.5 times the upper limit of normal, documented on two occasions (at least one month apart), within six months prior to enrollment
- Be HDV RNA positive by PCR (sensitivity: 103 copies/mL) [Yamashiro et al, 2004]
- Be HBV DNA positive by PCR
- Present with liver biopsy findings compatible with the diagnosis of chronic liver disease (the liver biopsy needs to be taken within 52 weeks prior to enrollment)
- Have adequate liver reserve (defined as equal to or better than Child-Pugh Class A)
- Present with WBC ≥3000/mm3, ANC ≥1500/mm3, and platelet ≥80,000/mm3
- Be able to and likely to attend regularly for treatment and follow-up
- Give their written informed consent
- Be negative for urine pregnancy test (for females of childbearing potential), documented once within the screening period and again within 24 hours prior to the first dose of study drug
- All male patients with female partners of childbearing age should use a barrier method of contraception
- All female patients of childbearing potential must use two reliable forms of effective contraception
Exclusion Criteria:
- Drug addicts or have any history or histological evidence of alcohol abuse, or currently receive prescriptions that may cause hepatotoxicity
- Have decompensated cirrhosis as coded by Child-Pugh classification (i.e. history of ascites, history of bleeding from esophageal varices, severe portal hypertension, serum albumin <30 g/l, serum bilirubin >30 mg/l)
- Present with WBC <3000/mm3, ANC <1500/mm3, or platelets <90,000/mm3
- Present with hemoglobin <12.0 gm/dl for female and <13.0 gm/dl for male
- Have been treated with immunosuppressive therapy within the past six months (e.g. steroids, azathioprine, cyclophosphamide)
- Have renal insufficiency (serum creatinine >150 μmol/l)
- Have clotting abnormalities which preclude a liver biopsy
- Have evidence of any serious neurological dysfunction
- Have obesity or diabetes mellitus-induced liver disease
- Have serological evidence of autoimmune chronic liver disease (e.g. antinuclear antibody titers >1:320, and/or smooth muscle antibody titers>1:160)
- Hemophiliacs
- Have evidence of inheritable disorders such as haemochromatosis, alpha-1-antitrypsin deficiency or Wilson's disease
- Have been exposed to hepatotoxic substances which might be the cause of hepatitis
- Pregnant, lactating or not practicing an adequate form of birth control, such as oral contraceptives or intrauterine devices
- Seropositive for anti-HIV or anti-HCV
- Have serious psychological or psychiatric problems disrupting daily activities
- Have AFP (alpha-fetoprotein) greater than 20 ng/ml; in case of elevated AFP, abdomen ultrasonography is required to exclude the possibility of HCC
- Have serious heart diseases (coronary heart disease, etc)
- Have a history of asthma or drug allergy which may lead to hypersensitivity to ribavirin
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
---|
the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B
|
二次結果の測定
結果測定 |
---|
the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate
|
The degree of histologic change
|
協力者と研究者
捜査官
- 主任研究者:Pei-Jer Chen, M.D., Ph.D.、National Taiwan University Hospital
研究記録日
主要日程の研究
研究開始
研究の完了
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 930904
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
慢性B型肝炎の臨床試験
-
Curocell Inc.募集高悪性度B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫(DLBCL) | 原発性縦隔大細胞型B細胞リンパ腫(PMBCL) | 形質転換濾胞性リンパ腫(TFL) | 難治性大細胞型B細胞リンパ腫 | 再発大細胞型B細胞リンパ腫大韓民国
-
Lapo Alinari募集MYC、BCL2、および BCL6 再構成を伴う再発高悪性度 B 細胞性リンパ腫 | MYC、BCL2、および BCL6 再構成を伴う難治性高悪性度 B 細胞性リンパ腫 | MYCおよびBCL2またはBCL6再構成を伴う再発性高悪性度B細胞リンパ腫 | MYCおよびBCL2またはBCL6再構成を伴う難治性高悪性度B細胞リンパ腫 | 再発性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型 | 難治性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型 | びまん性大細胞型B細胞リンパ腫への形質転換型無痛性B細胞非ホジキンリンパ腫 | 再発性びまん性大細胞型 B 細胞リンパ腫 胚中心 B 細胞型 | 難治性びまん性大細胞型...アメリカ
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.わからない
-
University of NebraskaBristol-Myers Squibb募集濾胞性リンパ腫 | 難治性非ホジキンリンパ腫 | 高悪性度B細胞リンパ腫 | DLBCL - びまん性大細胞型 B 細胞性リンパ腫 | 非ホジキンリンパ腫の再発 | 縦隔大細胞型B細胞リンパ腫 | 無痛性B細胞非ホジキンリンパ腫アメリカ
-
Nathan DenlingerBristol-Myers Squibb募集B細胞非ホジキンリンパ腫再発性 | びまん性大細胞型 B 細胞リンパ腫 - 再発性 | 濾胞性リンパ腫-再発性 | 高悪性度B細胞リンパ腫再発性 | 原発性縦隔大細胞型 B 細胞リンパ腫 - 再発性 | 緩徐進行性B細胞非ホジキンリンパ腫からびまん性大細胞型B細胞リンパ腫への転移 - 再発性 | B細胞非ホジキンリンパ腫難治性 | 難治性びまん性大細胞型 B 細胞リンパ腫 | 濾胞性リンパ腫難治性 | 難治性高悪性度B細胞リンパ腫 | 原発性縦隔大細胞型B細胞リンパ腫-難治性 | 緩徐進行性B細胞非ホジキンリンパ腫から難治性びまん性大細胞型B細胞リンパ腫への変化アメリカ
-
Athenex, Inc.募集B細胞リンパ腫 | CLL/SLL | すべて、子供時代 | DLBCL - びまん性大細胞型 B 細胞性リンパ腫 | B細胞白血病 | NHL、再発、成人 | ALL、成体 B 細胞アメリカ
-
Northwestern UniversityNational Cancer Institute (NCI)積極的、募集していないびまん性大細胞型B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫、特に特定されていない | 特に明記されていない高悪性度B細胞リンパ腫 | T細胞/組織球が豊富な大細胞型B細胞リンパ腫 | MYCおよびBCL2および/またはBCL6再構成を伴う高悪性度B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫活性化B細胞型 | びまん性大細胞型 B 細胞リンパ腫 胚中心 B 細胞型アメリカ
-
Patrick C. Johnson, MDAstraZeneca募集難治性B細胞非ホジキンリンパ腫 | びまん性大細胞型B細胞リンパ腫(DLBCL) | グレード3bの濾胞性リンパ腫 | 難治性攻撃性B細胞リンパ腫 | 攻撃的な B 細胞 NHL | De Novoまたは形質転換された無痛性B細胞リンパ腫 | DLBCL、Nos 遺伝子サブタイプ | T細胞/組織球が豊富な大細胞型B細胞リンパ腫 | EBV陽性のDLBCL、番号 | 原発性縦隔 [胸腺] 大細胞型 B 細胞性リンパ腫 (PMBCL) | 高悪性度 B 細胞性リンパ腫、Nos | C-MYC/BCL6 ダブルヒットの高悪性度 B 細胞性リンパ腫 | C-MYC/BCL2 ダブルヒットの高悪性度 B 細胞性リンパ腫アメリカ
-
Ohio State University Comprehensive Cancer Center募集びまん性大細胞型B細胞リンパ腫 | 高悪性度B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫、特に特定されていない | びまん性大細胞型 B 細胞リンパ腫 胚中心 B 細胞型アメリカ
-
National Cancer Institute (NCI)積極的、募集していない再発性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型 | 難治性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型アメリカ, サウジアラビア
pegylated IFN alfa-2b plus ribavirinの臨床試験
-
ANRS, Emerging Infectious DiseasesFlamel Technologiesわからない